BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

Boehringer Ingelheim logo

Boehringer Ingelheim

Status and phase

Phase 1


Leukemia, Lymphocytic, Chronic, B-Cell


Drug: BI 836826

Study type


Funder types



2010-021488-34 (EudraCT Number)

Details and patient eligibility


Adult patients with chronic lymphocytic leukaemia who experience a relapse after at least two prior treatment regimens may be enrolled in this trial. The trial will examine whether monotherapy with BI 836826 is safe and tolerable at escalating dose levels.


37 patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Diagnosis of relapsed or refractory chronic lymphocytic leukaemia.
  • At least two prior treatment regimens for chronic lymphocytic leukaemia.
  • At least one criterion for active disease as defined by the International Workshop on CLL.
  • Absolute lymphocyte count lower than 200 x 10^9/l .
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2.
  • Age 18 years or older.
  • Written informed consent which is consistent with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) guidelines and local legislation.

Exclusion criteria

  • Treatment with anti Cluster of Differentiation (CD) 20 therapy within 4 weeks, or alemtuzumab within 8 weeks, or any cytotoxic antileukemia therapy within 2 weeks, Ibrutinib or Idelalisib within 1 week prior to the first administration of the trial drug.
  • Prior allogeneic stem cell transplantation.
  • Active autoimmune haemolytic anemia.
  • Active autoimmune thrombocytopenia.
  • Known transformation to an aggressive B-cell malignancy.
  • Concurrent treatment with relevant doses of systemic glucocorticosteroids.
  • Prior history of malignancy other than chronic lymphocytic leukaemia (exceptions to this rule are defined in the clinical trial protocol).
  • Aspartate aminotransferase or alanine aminotransferase > 2.5 x upper limit of normal.
  • Total bilirubin > 1.5 x upper limit of normal.
  • Absolute Neutrophil Count < 1.000/µl.
  • Platelets < 25.000/µL.
  • Estimated Glomerular Filtration Rate <45 mL/min.
  • Proteinuria Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher.
  • Significant concurrent disease.
  • Any infectious disease requiring treatment at the time of enrolment or within the previous 2 weeks.
  • Hepatitis B or C.
  • Human Immunodeficiency Virus (HIV) infection.
  • Cytomegalovirus (CMV) viremia.
  • Women of childbearing potential not using a highly effective method of birth control during the trial until one year after the last dose.
  • Pregnancy or breast feeding.
  • Known or suspected active alcohol or drug abuse.
  • Treatment with another investigational drug within the past four weeks before start of therapy or concomitantly with this trial.
  • Prior treatment with BI 836826.
  • Patients unable to comply with the protocol

Trial design

37 participants in 1 patient group

Patients with relapsed CLL
Experimental group
Patients with relapsed CLL after at least two prior treatment regimens will receive BI 836826.
Drug: BI 836826

Trial documents

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems